Molecular mechanisms behind progressing chronic inflammatory dilated cardiomyopathy

Daiva Bironaite1*, Dainius Daunoravicius2, Julius Bogomolovas3, Sigita Cibiras2,5, Dalius Vitkus4, Edvardas Zurauskas2, Ieva Zasytyte5, Kestutis Rucinskas5, Siegfried Labeit3, Algirdas Venalis1 and Virginija Grabauskiene2,5

Abstract

Background: Inflammatory dilated cardiomyopathy (iDCM) is a common debilitating disease with poor prognosis that often leads to heart failure and may require heart transplantation. The aim of this study was to evaluate sera and biopsy samples from chronic iDCM patients, and to investigate molecular mechanism associated with left ventricular remodeling and disease progression in order to improve therapeutic intervention.

Methods: Patients were divided into inflammatory and non-inflammatory DCM groups according to the immunohistochemical expression of inflammatory infiltrates markers: T-lymphocytes (CD3), active-memory T lymphocyte (CD45Ro) and macrophages (CD68). The inflammation, apoptosis, necrosis and fibrosis were investigated by ELISA, chemiluminescent, immunohistochemical and histological assays.

Results: The pro-inflammatory cytokine IL-6 was significantly elevated in iDCM sera (3.3 vs. 10.98 μg/ml; P < 0.05). Sera levels of caspase-9, -8 and -3 had increased 6.24-, 3.1- and 3.62-fold, (P < 0.05) and only slightly (1.3-, 1.22- and 1.03-fold) in biopsies. Significant release of Hsp60 in sera (0.0419 vs. 0.36 ng/mg protein; P < 0.05) suggested a mechanistic involvement of mitochondria in cardiomyocyte apoptosis. The significant MMP9/TIMP1 upregulation in biopsies (0.1931 - 0.476, P < 0.05) and correlation with apoptosis markers show its involvement in initiation of cell death and ECM degradation. A slight activation of the extrinsic apoptotic pathway and the release of hsTnT might support the progression of chronic iDCM.

Conclusions: Data of this study show that significant increase of IL-6, MMP9/TIMP1 and caspases-9, -8, -3 in sera corresponds to molecular mechanisms dominating in chronic iDCM myocardium. The initial apoptotic pathway was more activated by the intramyocardial inflammation and might be associated with extrinsic apoptotic pathway through the pro-apoptotic Bax. The activated intrinsic form of myocardial apoptosis, absence of necrosis and decreased fibrosis are most typical characteristics of chronic iDCM. Clinical use of anti-inflammatory drugs together with specific anti-apoptotic treatment might improve the efficiency of therapies against chronic iDCM before heart failure occurs.

Keywords: Apoptosis, Dilated cardiomyopathy, Heart, Inflammation, Necrosis

Background
Inflammatory processes usually characterize myocarditis, the progression of which leads to development of dilated cardiomyopathy (DCM) causing heart failure and finally to heart tissue destruction [1,2]. Dilated cardiomyopathy (DCM) is a heart muscle disease which leads to the enlargement of one or both ventricles and consequent systolic dysfunction. DCM is a consequence of persistent exposure to various cellular stress signals, including pro-inflammatory, viral, oxidative, neuro-hormonal, and other micro- or macro environmental factors [3]. Accumulating data showed an importance of inflammatory component in the development of DCM, indicating a relation between myocarditis, autoimmunity and DCM even if immunosuppressive therapy is not always effective [4,5]. Therefore, a better understanding of the molecular mechanisms dominating in inflammatory DCM (iDCM) is needed in order to improve treatment and prevent further heart destruction.

* Correspondence: d.bironaite@imcentras.lt
1 Dept. of Stem Cell Biology, State Research Institute, Center for Innovative Medicine, Zygimantu 9, LT01102 Vilnius, Lithuania
2 Full list of author information is available at the end of the article
© 2015 Bironaite et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Pro-inflammatory cytokines are not constitutively expressed in the heart but are rapidly expressed in response to cardiac injury [6]. In most cases increased inflammation is in most cases a natural response to injury, helping to heal and recover damaged tissues, whereas overwhelming inflammation aggravates the disease [7]. High levels of accumulated pro-inflammatory factors induce various pathogenic effects, such as improper functioning of the left ventricle, cardiomyocyte death and/or fibrosis [8-10]. It was shown that inflammatory mediators, such as IL-6 and tumor necrosis factor - alpha (TNF-α) can activate apoptotic Fas-Fas ligand pathway in chronic heart failure [11]. Additionally, inflammatory cytokines activate members of the matrix metalloproteinase (MMP) family, zinc-depended endopeptidases, which participate in remodeling of ECM and fibrotic processes [12]. It is agreed, that likewise to heart failure, the main processes characterizing DCM are hypertrophy or loss/death of myocytes and interstitial fibrosis [13]. Despite of that, not all previously mentioned features fit to various forms of DCM. Therefore, in the present study, we have investigated the level of inflammation and subsequent induction of apoptosis, necrosis and fibrosis in sera and biopsies of chronic iDCM patients with purpose to estimate which of previously mentioned processes are mostly and firstly activated. A more detailed estimation of molecular mechanisms will allow more efficient use of therapeutic means to treat chronic iDCM and thereby prevent further myocardium destruction.

Methods

Inclusion and exclusion criteria

Study subjects were 32 consecutive patients (25 males, 7 females, mean age 43.14 ± 11.86 years), admitted to a tertiary referral Centre with clinically diagnosed DCM. All patients showed enlarged LV associated with significantly impaired systolic function (LVEF less 45%) on echocardiography in association with long duration of heart failure symptoms. At enrolment, the average duration of observed symptoms was 24–30 month. In addition to clinical severity of heart failure according to the New York Heart Association classification, heart failure was also identified by determination of concentration of brain natriuretic peptide (BNP) in sera.

Exclusion criteria: 1) Known causes of heart failure, such as hypertension, significant coronary artery disease, valvular heart diseases, although not relative mitral regurgitation, endocrine diseases, significant renal diseases or drug or alcohol abuse; 2) Acute myocarditis suspected by clinical presentation and diagnostic tests (signs or symptoms of systemic infections; elevated erythrocyte sedimentation rate, reactive C protein level and TnT/Tnl, acute chest pain with ST/T wave changes such as: ST-segment elevation or depression and T-wave inversions; new onset of non-specific ECG signs like: bundle branch block, AV-block and/or ventricular arrhythmias; regional wall motion abnormalities on echocardiography; edema and/or LGE on CMR).

All patients signed written informed consent for cardiac catheterization and endomyocardial biopsies (EMB), which includes resulting analysis to elucidate a possible origin of the myocardial and coronary artery diseases. Inflammatory cardiomyopathy was defined as a cardiomyopathy with decreased LVEF, increased LVEDD, and a positive myocardial inflammation score according to the Dallas criteria as well as criteria of the ESC/WHO [14-16]. All patients were subdivided into two groups: inflammation-positive (n = 22) and inflammation-negative (n = 10) according to immunohistochemically proven up-regulation of inflammatory infiltrate markers. CD3 (T lymphocyte), CD45Ro (active-memory T lymphocyte) and CD68 (macrophage) were determined immunohistochemically by counting positively stained cells per mm². Immunohistochemical stainings (IHC) of collected samples revealed the significant amounts of inflammatory cellular infiltrates ≥14 leucocytes/mm² including up to 4 monocytes/macrophages/mm² with the presence of CD3 positive T-lymphocytes ≥7 cells/mm² in the biopsy samples (Figure 1). A cut off for inflammation samples (diffuse, focal or confluent) and the presence or the absence of necrosis and fibrosis were determined as earlier described [15].

Additional medical examinations

All patients were interviewed about their medical history and underwent a careful physical examination, as well as laboratory studies, including test of thyroid function, serum electrolytes (sodium, potassium), hsCRP, glucose, HbA1c, cholesterol, triglyceride, HDL, LDL, cardiac enzymes (CK, CK-MB, AST), hsTnT, urea, creatinine, uric acid, coagulation tests (PT, aPTT), blood count (hemoglobin, haematocrit, RBC, WBC and platelet count). Each patient underwent investigations such as blood pressure on admission, ECG, echocardiography, Holter monitoring and spiroergometry. The same basic medical treatment scheme was applied to all patients. Essential physical and laboratory data are shown in Table 1.

Cardiac catheterization and endomyocardial biopsies

Before EMB, each patient underwent coronary angiography to exclude coronary artery disease as well as right heart catheterization to assess haemodynamic parameters: mean pulmonary artery (PA) pressure, pulmonary capillary wedge pressure (PCWP) and pulmonary vascular resistance (PVR). Right ventricular EMB was obtained using a flexible bioptome via the right
Figure 1 (See legend on next page.)
femoral vein [17]. Myocardial dilatation was assessed by ultrasound. Biopsies were taken from the right inter-ventricular septum from patients with confirmed absence of ischemia and cardiovascular pathology (stenosis and occlusion). Biopsy specimens were immediately placed at −80°C and later processed for appropriate studies. At least three EMBs samples were subjected to the conventional histological and immunohistochemical evaluation, while two EMBs were stored in a biobank as retained biosamples. Blood collection tubes (8.5 ml) were used for serum sampling of each patient at the same time as EMB.

Preparation of blood samples
Collected blood samples were placed in vacutainer tubes without anticoagulants and kept at room temperature for 30–45 min to allow clotting. Samples were centrifuged for 15 min at the manufacturer’s recommended speed (1,000 - 2,000 RCF). The upper layer was carefully aspirated, checked for turbidity, aliquoted into cryovials, labeled and stored at −80°C. Before measurement, all serum samples were thawed on ice, centrifuged at 12,000 g for 5 min and, if necessary, appropriately diluted.

Biochemical assays of inflammatory infiltrates and cytokines
Inflammatory infiltrates were estimated on fixed, paraffin-embedded material. For classification of biopsies, the previously mentioned markers (Santa Cruz Biotechnology, Inc.), CD3 (T lymphocytes), CD45Ro (active-memory T lymphocytes) and CD68 (macrophages) were applied. Positive cells were registered by an experienced pathologist and expressed as number of cells per mm². The pro-inflammatory cytokines TNF-α, IL-6 and IL-1β in serum samples were assayed by solid-phase, chemoluminescent immunometric assays using IMMULITE/Immulite 1000 systems (Immulite, Siemens).

Table 1 Baseline characteristics of patients

| Variable                  | Inflammation negative group | Inflammation positive group | p Value |
|---------------------------|-----------------------------|----------------------------|---------|
| Sex (male/female)         | Total No. of pts. | Value | Total No. of pts. | Value | p Value |
| Sex (male/female)         | 10                         | 8 (80%) / 2 (20%)          | 22      | 17 (77%) / 5 (33%)          | 0.863¿ |
| Age (years)               | 10                         | 46.7 ± 5.87                | 22      | 42.36 ± 2.07                | 0.389  |
| NYHA                      | 10                         | 1 (10%)                    | 22      | 0 (0%)                      | 0.132¿ |
| NYHA                      | 10                         | 7 (70%)                    | 22      | 15 (68%)                    | 0.918¿ |
| LVBB (%)                  | 10                         | 3 (30%)                    | 22      | 5 (22.7%)                   | 0.659¿ |
| Permanent AF (%)          | 10                         | 2 (20%)                    | 22      | 0 (0%)                      | 0.000¿*|
| LVEF (%)                  | 10                         | 24.10 ± 2.28               | 22      | 23.05 ± 1.35                | 0.678  |
| LVEDD (cm)                | 10                         | 6.89 ± 0.17                | 22      | 6.89 ± 0.19                 | 0.998  |
| LVEDDD (cm/m²)            | 10                         | 3.68 ± 0.21                | 22      | 3.71 ± 0.09                 | 0.847  |
| Mean Ao (mmHg)            | 10                         | 92.00 ± 3.95               | 22      | 86.06 ± 2.71                | 0.291  |
| Mean RAP (mmHg)           | 10                         | 16.22 ± 3.19               | 22      | 11.44 ± 1.74                | 0.164  |
| Mean PCWP (mmHg)          | 10                         | 25.00 ± 2.79               | 22      | 23.45 ± 2.70                | 0.731  |
| Mean PAP (mmHg)           | 10                         | 34.89 ± 4.33               | 22      | 32.95 ± 3.24                | 0.734  |
| CI (L/min/m²)             | 10                         | 2.38 ± 0.33                | 22      | 2.2 ± 0.14                  | 0.573  |

Data are presented as the means ± SE. *Significant at 0.05 level. ¿Chi-square test. Abbreviations: NYHA – New York Heart Association functional class; LBBB – left bundle branch block; AF – atrial fibrillation; LVEF - left ventricular ejection fraction; LVEDD – left ventricular end-diastolic diameter; LVEDDI – left ventricular end-diastolic diameter index; Ao – aortic; RAP – right atrial pressure; PCWP – pulmonary capillary wedge pressure; PAP – pulmonary artery pressure; CI – cardiac index.
according to the manufacturers’ instructions: TNF-α (Catalog No: LKNFZ (50 tests), LKNF1 (100 tests); IL-6 (Catalog No: LK6PJZ (50 tests), IL-1β (Catalog No: LKL1Z (50 tests)).

Biochemical assays for apoptosis and necrosis
ELISA was used to assay endomyocardial biopsies and serum samples. The following biomarkers were analyzed: Bcl-2, caspase-9, caspase-8 (Novus Biologicals Europe, Cambridge, UK); Bax (Elabscience Biotechnology Co., Ltd, China); caspase 3, MMP9, TIMP1, APO1/Fas/CD95, FasL (Invitrogen, Paisley, UK) and HSP60 (AssayPro, Saint Charles, Missouri, USA).

Collected heart tissue biopsies were immediately inserted into clean tubes and kept at −80°C. Before measurement, tissue samples were thawed on ice, appropriately diluted and analyzed by ELISA.

All collected serum samples were centrifuged at 12,000 g for 5 min, aliquoted in 50 µl portions and stored at −80°C. Before measurement, serum samples were thawed on ice, appropriately diluted and analyzed by ELISA.

Amount of protein in serum and biopsy samples were measured using a modified Lowry Protein Assay kit according to the manufacturer’s recommendations (Thermo scientific Inc., USA). Absorbance was measured with a spectrophotometer (Asys UVM 340 Microplate Reader UK - Biochrom Ltd.) set to 750 nm. The exact protein concentration of each unknown sample was estimated using bovine serum albumin (BSA) as a standard. Total protein concentrations were expressed as µg/ml. Final concentration of biomarkers was expressed as ng/mg of protein or pg/mg protein.

The myocardial injury marker, high-sensitivity troponin T (hsTnT), was measured in serum using an Elecsys 2010 analyzer (Roche Diagnostics, Indianapolis, Indiana) and expressed as pg/ml. Myocardial necrosis was estimated and scored by a competent pathologist on at least three independent routinely stained (Haematoxylin and Eosin (H&E) sections. Normal myocardial fibers had peripheral nuclei, intact sarcolemma and non-fragmented nuclei. Pyknosis of muscle fiber nuclei, edema, and beginning of leuco-diapedesis from the capillaries suggested that the myocardial cells had reached the stage of necrosis.

Histochemical measurement of fibrosis in endomyocardial biopsies
Tissues collected for histological analyzes were fixed in 10% neutral buffered formalin, and then paraffin-embedded in a tissue processor. Total cardiac fibrosis (including interstitial and perivascular forms) was assessed. Specimens were stained with Masson’s trichrome connective tissue stain according to a standard protocol. Keratin and normal muscle fibers stained red, whereas fibrotic areas stained blue. Digital images from the experimental glass slides were obtained using ScanScope Digital Slide Scanner (Aperio, Vista, CA) at a 20× magnification and archived on a devoted Spectrum Server 11.1.0.751 (Aperio). Quality control of the scanned images and all further analysis were performed using ImageScope V11.1.2.760 (Aperio) and WebScope V11.1.0.756 (Aperio).

Digital analysis of the slides was done using a Colocalization V9 algorithm that was run for the whole slides, ignoring the number of tissue cross sections on it – making the process fully automated. A colocalization algorithm uses the deconvolution method to separate the stains and classifies each pixel according to the number of stains present. For colocalization, the threshold for each stained sample is specified for a required stain (e.g. Masson’s trichrome) and the algorithm reports the percentage of areas for each stain combination is detected: 1, 2, 3, 1 + 2, 1 + 3, 2 + 3, 1 + 2 + 3 or none (up to 3 areas were analyzed). The algorithm also provides an eight-color mark-up image for visualization of colocalized stains. Summing up the stain combinations 3, 2 + 3 and 1 + 3 calculated the total percentage of cardiac fibrosis.

PCR assay
Intramyocardial viruses were estimated by PCR assay [18]. Briefly, genomic DNA and total RNA were extracted simultaneously using ZR-Duet™ DNA/RNA Miniprep kit (Zymo Research, Irvine, CA, USA). RNA (1 µg) was reversely transcribed in 20 µl reaction volumes using random hexamers and First Strand cDNA Synthesis Kit (Thermo Fisher, Vilnius, Lithuania) according to the vendor’s recommendations. Forward primers for the second round of PCR were labeled with 6-carboxyfluorescein (FAM) at the 5’ end. Final PCR products were 10-fold diluted and analyzed by capillary electrophoresis on a Genetic Analyzer 3130xl, using GeneScan™ 600 LIZ™ Size Standard and Gene Mapper Software v4.1 (Applied Biosystems, Foster City, CA, USA) for sizing PCR fragments. The following virus species were detected in the biopsies of 16 patients: parvo virus B19 (n = 11), human herpes virus type 6 (n = 4), hepatitis C virus (n = 1), Epstein-Barr virus (n = 1), enterovirus (n = 1), and varicella zoster virus (n = 1). The frequencies of detected viral genomes were equal in each tested group (50%) and, therefore, it did not influence the results.
Statistical analysis
All statistical analyses were performed using the SPSS package (version 19.0 for Windows; SPSS Inc., Chicago, IL, USA) at not higher than 5% significance level. The normality of the data distribution was tested by the Shapiro-Wilk test. Significance of measurements was tested by Student’s t test or the Wilcoxon–Mann–Whitney rank sum non-parametric test. For comparative purposes Pearson’s correlation coefficient was used.

Ethical approval
The study was approved by the local Lithuanian Bioethics Committee (license No. 158200-09-382-l03; No. 158200-382-PP1-23). All patients signed written informed consent to include their data in the study for each investigational procedure. The investigation conforms to the principles outlined in the Declaration of Helsinki.

Results
Inflammatory markers in dilated cardiomyopathy
Here, we monitored the inflammatory process by detecting expression of CD3, CD45Ro and CD68 in inflammatory infiltrates by immunohistochemistry (Figure 1). In addition, we determined levels of inflammatory cytokines TNF-α, IL-6 and IL-1β in sera. Representative immunohistochemical micrographs show the increased and diffused expression of CD3, CD45Ro and CD68 (Figure 1A, B, C, D, E and F). Total expression of cytokines in infiltrates from inflammatory-negative and -positive groups is shown in Figure 1G. T-lymphocyte receptors (CD3) and active memory T-lymphocytes (CD45Ro) were significantly upregulated 2.38-fold ($P < 0.001$) and 2.1-fold ($P < 0.01$), respectively (Figure 1G). Significant accession of CD3 and CD45Ro in iDCM myocardium also suggests increased myocardial micro-vascular permeability.

Our data showed upregulation of the specific and general inflammatory markers interleukin-6 (IL-6) and C-reactive protein (hsCRP), respectively, in iDCM serum samples (3.45-fold, $P < 0.05$ and 2.76-fold) (Table 2). Changes of tumor necrosis factor alpha (TNF-α) and interleukin-1beta (IL-1β), also known as catabolin, were not significant in the iDCM sera.

Changes of apoptotic and necrotic biomarkers in iDCM samples
Data presented in Figure 2A show significant correlation between CD3 and IL-6. Significant correlation of IL-6 and hsCRP with the mitochondrial chaperonic protein Hsp60 and pro-apoptotic Bax in sera, respectively, suggests that myocardial inflammation mostly affected the integrity of mitochondrial membranes (Figure 2B and C). Levels of the mitochondrial membrane stabilizing protein Hsp60 in inflammation-positive sera were 8.97-fold higher ($P < 0.05$). Changes of APO1/Fas/CD95 (FasR), the main receptor of extrinsic apoptotic pathway, and its ligand (FasL) in sera and biopsies were not significant (Table 2).

Data presented in Figure 3A demonstrate statistically significant ($P < 0.05$) increase of caspase-9, ~8 and ~3 in sera with the most prominent expression of caspase-9. Enhanced expression of the same caspases in endomyocardial biopsy samples (Figure 3B) was, however, slight and insignificant. The upregulation of high sensitivity troponin T (hsTnT), a major structural sarcomeric protein of the heart and a marker of necrosis and/or cardiomyocyte injury, in sera was not significant (Table 2). However, the sarcomeric protein hsTnT in iDCM sera strongly correlated with the levels of caspases-8, Bax and caspase-3 in biopsies, suggesting cardiomyocyte injury and caspase-regulated release of hsTnT (Table 3).

The correlation analysis of apoptotic biomarkers in iDCM sera and biopsies
Data in Figure 4A demonstrate that caspase-9, a serum cysteine-aspartic acid specific protease, also named apoptosis-initiating caspase, significantly correlated with the general inflammatory marker C-reactive protein (hsCRP) confirming the sensitivity of the intrinsic apoptotic pathway to inflammation. In parallel, the significant correlation between caspase-9 and MMP9 tells us that caspase-9 might be either directly activated by the MMP9 or, alternatively, through the other mediators of the intrinsic apoptotic pathways, such as Bcl-2 and Bax (Figure 4C and D; $P < 0.05$). Results presented in Figure 4E and F show that levels of caspase-9 are strongly correlated ($P < 0.05$) with the executing caspase-3 and extrinsic apoptotic pathway-initiating caspase-8, suggesting the interaction between the intrinsic and extrinsic apoptotic pathways. Furthermore, a significant correlation was observed between caspase-8 and the APO1/Fas/CD95 levels in iDCM sera (Figure 5A). Caspase-8 also significantly correlated with the pro-apoptotic Bax and MMP9 confirming the intersection of extrinsic and intrinsic pathways at mitochondrial level and caspase-8 activation by MMP9 (Figure 5B and C).

Next, we have investigated correlation of apoptotic biomarkers in iDCM myocardium. Caspase-9 in heart tissues, similarly to that in sera, significantly correlated with pro-inflammatory cytokine IL-6, and caspase-8 in myocardium correlated with Bax and caspase-3 (Table 3). The executing caspase-3 also demonstrated significant correlation with both the intrinsic (Bax, Bcl-2) and extrinsic (APO1/Fas/CD95 and FasL) apoptotic pathways (Table 3). Similarly to that in sera, members of both apoptotic pathways (Bcl-2, APO1/Fas/CD95 and FasL) in biopsies significantly correlated with MMP9 and its inhibitor TIMP1 (Table 3).
### Table 2: Summarized data of measured biomarkers

| Variable | Inflammation negative group | Inflammation positive group | p Value |
|----------|------------------------------|-----------------------------|---------|
|          | Total No. of pts. | Value          | Total No. of pts. | Value          |         |
| **Markers of inflammation in serum** |         |                             |         |                             |         |
| TNF-α (pg/mL) | 8 | 7.9313 ± 0.5106 | 21 | 14.2819 ± 5.0280 | 0.223 |
| IL-6 (pg/mL)   | 8 | 3.3938 ± 0.8554 | 21 | 11.4038 ± 3.3614 | 0.031* |
| IL-1β (pg/mL)  | 8 | 5.0000 ± 0.0000 | 21 | 4.7619 ± 0.2381 | 0.329 |
| CRP (μg/mL)    | 8 | 7.6875 ± 5.0460 | 19 | 21.5563 ± 6.9633 | 0.066 |
| **Markers of apoptosis in serum** |         |                             |         |                             |         |
| Bcl2 (ng/mg protein) | 10 | 0.0288 ± 0.0288 | 22 | 0.0536 ± 0.0455 | 0.889 |
| Bax (ng/mg protein)  | 10 | 2.152717 ± 0.24 | 22 | 2.3354 ± 0.1606 | 0.535 |
| Caspase-9 (ng/mg protein) | 10 | 0.012955 ± 0.0013 | 22 | 0.0808 ± 0.0283 | 0.038* |
| Caspase-8 (ng/mg protein) | 10 | 0.001 ± 0.0001 | 22 | 0.0031 ± 0.0009 | 0.043* |
| Caspase-3 (ng/mg protein) | 10 | 0.0029 ± 0.0022 | 22 | 0.0105 ± 0.0023 | 0.025* |
| APO1/Fas/CD95 (ng/mg protein) | 10 | 0.0000 ± 0.0000 | 22 | 0.00004 ± 0.00004 | 0.857 |
| Fasl (ng/mg protein) | 10 | 0.0000 ± 0.0000 | 22 | 0.0000 ± 0.0000 | N.A. |
| HSP60 (ng/mg protein) | 10 | 0.0419 ± 0.0253 | 22 | 0.3760 ± 0.1468 | 0.035* |
| **Markers of apoptosis in biopsy** |         |                             |         |                             |         |
| Bcl2 (ng/mg protein) | 10 | 83.5523 ± 26.2936 | 21 | 63.8790 ± 17.2137 | 0.540 |
| Bax (ng/mg protein)  | 10 | 5.6452 ± 2.6905 | 21 | 6.8873 ± 3.7924 | 0.724 |
| Caspase-9 (ng/mg protein) | 10 | 29.6575 ± 12.5969 | 21 | 38.7122 ± 9.6108 | 0.950 |
| Caspase-8 (ng/mg protein) | 10 | 0.9483 ± 0.1640 | 21 | 1.1611 ± 0.1962 | 0.413 |
| Caspase-3 (ng/mg protein) | 10 | 0.2503 ± 0.0773 | 21 | 0.2586 ± 0.0649 | 0.935 |
| APO1/Fas/CD95 (ng/mg protein) | 10 | 3.4651 ± 0.6568 | 21 | 4.1921 ± 0.6607 | 0.443 |
| Fasl (ng/mg protein) | 10 | 4.5550 ± 1.3594 | 21 | 4.0588 ± 1.1083 | 0.780 |
| HSP-60 (ng/mg protein) | 10 | 24.1262 ± 6.9102 | 21 | 19.2656 ± 4.5617 | 0.565 |
| **Marker of heart tissue contraction in serum** |         |                             |         |                             |         |
| hsTnT (pg/mL) | 8 | 35.4988 ± 9.0908 | 20 | 66.4145 ± 26.9755 | 0.289 |
| **Markers of extracellular matrix degradation in serum** |         |                             |         |                             |         |
| MMP9 (ng/mg protein) | 10 | 1.3867 ± 0.0674 | 22 | 1.5261 ± 0.0508 | 0.115 |
| TIMP1 (ng/mg protein) | 10 | 5.9610 ± 0.3597 | 22 | 6.1223 ± 0.1497 | 0.686 |
| MMP9/TIMP1 | 10 | 0.2355 ± 0.0090 | 22 | 0.2511 ± 0.0086 | 0.223 |
| **Markers of extracellular matrix degradation in biopsy** |         |                             |         |                             |         |
| MMP9 (ng/mg protein) | 10 | 2.3698 ± 1.1931 | 21 | 2.7630 ± 0.9394 | 0.798 |
| TIMP1 (ng/mg protein) | 10 | 9.4917 ± 1.7605 | 21 | 7.8056 ± 1.4029 | 0.462 |
| MMP9/TIMP1 | 10 | 0.1931 ± 0.0729 | 21 | 0.4760 ± 0.1048 | 0.035* |
| Frequency of viral genome | 5 | 50% | 11 | 50% |         |
| BNP (pg/mL) | 10 | 1277.8500 ± 428.5054 | 22 | 1603.2591 ± 276.3777 | 0.532 |

Data are presented as the means ± SE. *Significant at 0.05 level. †Wilcoxon–Mann–Whitney rank sum nonparametric test. Abbreviations: TNF-α – tumor necrosis factor α; IL-6 – interleukin-6; IL-1β – interleukin 1β; Bcl-2 – B-cell lymphoma 2 protein; Bax – Bcl-2-associated X protein; Hsp60 – heat shock protein 60; MMP9 – matrix metalloproteinase 9; TIMP1 – tissue inhibitor of matrix metalloproteinase 1; TNF-α – tumor necrosis factor alpha; IL-1β – interleukin 1 beta; IL-6 – interleukin 6; hs TnT – high sensitivity troponin T; CRP – C-reactive protein; BNP – B-type natriuretic protein; N.A. – not available.

Estimation of fibrosis in iDCM biopsies

The final experimental part was dedicated to investigate the level of fibrosis in the EMB samples. Data in Figure 6A and B show that the level of fibrosis (blue stain) in inflammatory-positive biopsies was slightly lower compared to the inflammatory-negative ones. The quantitative expression of fibrosis staining confirmed our observation (Figure 6C). The exact roles of collagen I
and III in fibrosis were impossible to evaluate due to the absence of collagen I and III quantification algorithm under polarized light. This part needs additional investigations.

**Discussion**

Inflammatory cardiomyopathy is often defined by myocarditis in association with cardiac dysfunction and inflammation as a main factor of interconnection [15,19]. Long-term studies have shown that less than 15% of patients with acute myocarditis developed dilated cardiomyopathy [20]. It was also demonstrated that patients with proved active myocarditis in biopsies and idiopathic DCM had the same long-term outcome (56% vs. 54%, respectively) [21]. Therefore, investigation of underlying basic molecular mechanisms and their possible pharmacological modulation could improve treatment of chronic iDCM.

Formerly the inflammatory markers were thought to be only indicators of risk but not causal factors [22]. However, it was shown that the pro-inflammatory cytokines, such as TNF-α, IL-6 and IL-1β, might act synergistically at both mRNA and protein levels by impairing cardiac contraction [23,24]. Pro-inflammatory IL-6 has been reported to be involved in the remodeling of left ventricle after myocardial infarction and induced heart failure leading to skeletal muscle atrophy and heart disorders [25,26]. The molecular mechanisms by which IL-6 affect myocardium can be related to a negative ionotropic effect and upregulation of nitric oxide synthase, downregulation of SERCA2, stimulation of collagen synthesis to name a few [27-29]. The activation of molecular mechanism in heart usually depends on the origin, duration and intensity of toxic stimuli.

Recently, a strong and direct influence of IL-6 was shown on mitochondrial function: IL-6 inhibited adipocyte mitochondrial membrane potential, ATP production and increased intracellular ROS levels [30,31]. Similar to IL-6, a general inflammatory biomarker C-reactive protein (hsCRP) also correlated with poor DCM prognosis, heart failure and mitochondrion-mediated

---

**Figure 2** Correlation between inflammatory and mitochondrial membrane destabilization markers. (A) Correlation between serum inflammatory cytokine IL-6 and CD3. (B) Correlation between IL-6 and mitochondrial membrane stabilizing chaperone Hsp60 in serums. (C) Correlation between C-reactive protein (CRP) and Bax in serums. Correlation analysis was done by the statistical SPPS programme. Correlation was significant at a level of $P < 0.05$. Linear regression line is presented within 95% confidence interval. Regression coefficients ($R^2$) are shown in the graphs.
myocyte apoptosis [32-34]. It was also shown that, CRP contributes to IL-6 expression which is a stronger prognostic predictor of heart failure than CRP [35,36]. In agreement with previous observations, our data show significant upregulation of IL-6 in chronic iDCM sera and its significant correlation with numbers of infiltrated T-lymphocytes (CD3) and secreted intra-mitochondrial Hsp60 protein levels. The significant correlation of CRP with pro-apoptotic Bax and strong upregulation of caspase-9 in sera confirmed that inner apoptotic pathway is more sensitive to inflammation compared to the extrinsic one. Additionally, the absence of necrosis and insignificant upregulation of apoptosis markers in biopsies suggest the beginning of cell death in chronic iDCM myocardium.

Table 3 Correlation of apoptotic, necrotic and inflammatory biomarkers in EMB

|                       | Casp-9 in biopsy | Casp-8 in biopsy | Casp-3 in biopsy | Bcl2 in biopsy | FasR in biopsy | FasL in biopsy | MMP9 in biopsy | TIMP1 in biopsy | Bax in biopsy | IL-6 in serum |
|-----------------------|------------------|------------------|------------------|---------------|---------------|---------------|---------------|---------------|--------------|--------------|
| Casp-8 in biopsy       | 0.303            |                  |                  |               |               |               |               |               |              |              |
| Casp-3 in biopsy       |                  | 0.436*           |                  |               |               |               |               |               |              |              |
| Bcl2 in biopsy         | −0.202           | 0.175            | 0.486*           |               |               |               |               |               |              |              |
| FasR in biopsy         | −0.097           | −0.074           | 0.526*           | 0.739**       |               |               |               |               |              |              |
| FasL in biopsy         | −0.046           | 0.007            | 0.442*           | 0.835**       | 0.907**       |               |               |               |              |              |
| MMP9 in biopsy         | −0.229           | 0.024            | 0.419            | 0.764**       | 0.730**       | 0.824**       |               |               |              |              |
| TIMP1 in biopsy        | −0.012           | −0.205           | 0.213            | 0.517*        | 0.795**       | 0.722**       | 0.401         |               |              |              |
| Bax in biopsy          | 0.283            | 0.584**          | 0.678**          | 0.056         | 0.139         | 0.053         | 0.128         | −0.127        |              |              |
| IL-6 in serum          | 0.518*           | −0.016           | −0.011           | −0.262        | −0.202        | −0.154        | −0.041        | −0.227        | 0.131        |              |
| hs TnT in serum        | 0.434            | 0.598**          | 0.563*           | −0.125        | −0.067        | −0.165        | −0.120        | −0.249        | 0.954**      | 0.231        |

Two tailed significance: *P < 0.05; **P < 0.01. Significant correlations are in bold type.

Abbreviations: Casp-3 – Caspase-3; Casp-8 – Caspase-8; Casp-9 – Caspase-9; IL-6 – Interleukin-6; Bcl-2 – B-cell lymphoma 2 protein; FasR – Fas receptor; FasL – Fas ligand; MMP9 – matrix metalloproteinase 9; TIMP1 – tissue inhibitor of matrix metalloproteinase 1; Bax – Bcl-2-associated X protein; Hsp60 – heat shock protein 60; hsTnT – high sensitivity Troponin T.
Many recent findings demonstrate interaction between both apoptotic pathways strengthening toxic effects in heart [37]. It was shown that the member of the extrinsic apoptotic pathway pro-caspase-8 cleaves the BH3 domain-only protein Bid, which in turn, activates Bax, stimulates its integration into mitochondrial membranes and release of cytochrome c [38,39]. In agreement with previous observations, data of the present study show a significant correlation between caspase-8 and Bax levels in iDCM sera, suggesting that Bax can be one of the most important intersection points between the intrinsic and extrinsic apoptotic pathways. However, the mediators of extrinsic apoptotic pathway in iDCM samples had low initial level and intensity of activation suggesting this pathway being a supporter but not a main leader of heart cell death. The other authors’ observations confirmed that the extrinsic apoptotic pathway might have low impact on cardiomyocyte death in left ventricular tissue [40].

The ECM is an important mediator between different cell types within the myocardium supporting its structural network which can be degraded by proteolytic enzymes matrix metalloproteinases (MMPs). In animal
model, a time-dependent increase of myocardial MMPs levels were related to the progression of left ventricular dilation and dysfunction [41]. Similar to the intrinsic apoptotic pathway, MMP-9 was also found to be sensitive to inflammation and to participate in the pathogenesis of cardiomyopathy [42]. Additionally, it was shown that chronic heart failure involves endothelial apoptosis in response to MMP-9 activation [43]. Data of this study showed that the MMP-9/TIMP1 ratio in iDCM biopsies was significantly upregulated and significantly correlated with the markers of both apoptotic pathways (Bcl-2, Fas receptor and Fas ligand). These observations suggest that upregulation of MMP-9/TIMP1 are more related to the activation of apoptotic pathways than to the stimulation of fibrosis. Parallely, the significant correlation between hsTnT and apoptotic proteins caspases-8, Bax and caspase-3 also reveals hsTnT contribution to the impairment of cardiomyocyte and/or contraction ability by activation of pro-apoptotic signaling cascades.

Conclusions
The present study demonstrates that persistent myocardial stressors increase T-lymphocytes in myocardium of iDCM patients which correlates with the augmented secretion of inflammatory cytokines, such as IL-6. Chronic myocardial inflammation subsequently affects mitochondria and induces significant release of Hsp60 and caspase-9, −8 and −3, suggesting activation of both apoptotic pathways with stronger implication on the intrinsic pathway. The pro-apoptotic Bax is an important intersection point for the extrinsic- and intrinsic apoptotic pathways, blockade of which might improve iDCM treatment. The significant activation of MMP-9/TIMP1 was enough to support apoptosis but not fibrosis.

Taken together, our study suggests that biomarkers secreted to the serum parallels intramyocardial processes and, therefore, might be useful not only for the diagnosis but also for detailed studies of the molecular mechanism behind chronic iDCM. The observed absence of necrosis and fibrosis in chronic iDCM shows that disease had still not reached an end-stage and might be controlled by anti-inflammatory and specific anti-apoptotic drugs.

Limitations
The main limitation of this study is that it contains a relatively low number of iDCM patients. The study also
lacks normal heart biopsies because of ethical reasons. However, the main goal of this study was to investigate the main processes, molecular mechanism and signaling pathways dominating in chronic iDCM of unknown origin. The collection of additional iDCM samples continues and, hopefully, in the future we will be able to understand more about iDCM diagnosis and its treatment.

Figure 6 Histopathological findings of fibrosis in right ventricular EMB. (A) Inflammation-negative EMB. (B) Inflammation-positive EMB. (C) Quantitative expression of fibrosis. Micrographs show one representative picture from one patient of each group. Fibrosis is colored blue. Magnification × 10.
Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

DB and DD drafted the manuscript. DD performed statistical analysis. SC, KR and DV performed cardiac catheterization and collection of sera and EMB samples. DB performed serum- and EMB ELISA analyses. EZ performed microscope evaluation of the samples. DD designed and performed the digital analyses. IQ - selected patients. JB and SL - participated in the consideration of results. AV - provided with laboratory equipment. AG - manager of study. All authors have participated in conception and design of the study, reviewed the analysis of results as well as read and approved the final manuscript.

Acknowledgements

This work was supported by the Research Council of Lithuania (grant number: MIP-086/2012 and MIP-011/2014) and European Union, EU-FP7, SarcoSi project (number: 291834) for support.

Author details

1Dept. of Stem Cell Biology, State Research Institute, Center for Innovative Medicine, Zigimantas 9, LT01102 Vilnius, Lithuania. 2Department of Pathology, Forensic Medicine and Pharmacology, Vilnius University, Faculty of Medicine, Vilnius, Lithuania. 3Department of Integrative Pathophysiology, Universitätsmedizin Mannheim, Mannheim, Germany. 4Department of Physiology, Biochemistry, Microbiology and Laboratory Medicine, Vilnius University, Faculty of Medicine, Vilnius, Lithuania. 5Vilnius University, Faculty of Medicine, Clinic of Cardiovascular Diseases, Vilnius, Lithuania.

Received: 20 October 2014 Accepted: 27 February 2015

Published online: 26 March 2015

References

1. Mason JW. Myocarditis and dilated cardiomyopathy: an inflammatory link. Circ Cardiovasc Res. 2003;50:65–10.
2. Gopal DM, Sam F. New and emerging biomarkers in left ventricular systolic dysfunction-insight into dilated cardiomyopathy. J Cardiovasc Transl Res. 2013;6:516–27.
3. Maisch B, Noutsias M, Ruppert V, Richter A, Pankuweit S. Cardiomyopathies: classification, diagnosis, and treatment. Heart Fail Clin. 2012;28:53–78.
4. Kawai C. From myocarditis to cardiomyopathy: mechanisms of inflammation and cell death: learning from the past for the future. Circulation. 1999;99:1091–100.
5. Mason JW, O’Connell JB, Henskowitz A, Rose NR, McManus BM, Billingham ME, et al. A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. N Engl J Med. 1995;333:269–75.
6. Kapadia S, Lee JR, Torre-Amione G, Birdsal HH, Ma TS, Mann DL. Tumor necrosis factor gene and protein expression in adult feline myocardium after endotoxin administration. J Clin Invest. 1995;96:1042–52.
7. Eddy LJ, Goeddel DV, Wong GHW. Tumor necrosis factor-α pretreatment is protective in a rat model of myocardial ischemia-reperfusion injury. Biochem Biophys Res Commun. 1992;184:1056–9.
8. Schwimmer BL, Badoff C, Rohr G, Schulze K, Schulteis HP. The role of sensitized T-cells in myocarditis and dilated cardiomyopathy. Int J Cardiol. 1996;54:117–25.
9. Yamaji K, Fujimoto S, Ikeda Y, Masuda K, Nakamura S, Saito Y, et al. Apoptotic myocardial cell death in the setting of arrhythmogenic right ventricular cardiomyopathy. Acta Cardiol. 2005;60:440–65.
10. Leslie KO, Schwartz J, Simpson K, Huber SA. Progressive interstitial collagen deposition in Coxackievirus B3-induced murine cardiomyopathy. Am J Pathol. 1990;136:683–93.
11. Kinugawa T, Kato M, Yamamoto K, Hisatome I, Nohara R. Proinflammatory cytokine activation is linked to apoptotic mediators, soluble fas level in patients with chronic heart failure. Int Heart J. 2012;53:182–6.
12. Toprak G, Yüksel H, Demirpolat O, İslamoglu Y, Evlsayoglu O, Mete N. Fibrosis in heart failure subtypes. Eur Rev Med Pharmacol Sci. 2017;21:2302–9.
13. Davies MJ, McKenna WJ. Dilated cardiomyopathy: an introduction to pathology and pathogenesis. Br Heart J. 1994;72:524.
14. Caforio AL, Pankuweit S, Arbustini E, Basso C, Girmeno-Blanes J, Felix SB, et al. European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2013;34:2636–48. 2644a-2648d.
15. Karátolósi K, Pankuweit S, Kisselbach C, Maisch B, Hellenic J. Inflammatory cardiomyopathy: Hellenic J. Cardiol. 2006;4:55A-65.
16. Richardson P, McKenna WJ, Bristow MR, Maisch B, Mautner B, O’Connell J, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation. 1996;93:841–2.
17. Cooper LT, Baughman KL, Feldman AM, Frustaci A, Jessup M, Kuhl U, et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Circulation. 2007;116:2216–33.
18. Allard A, Albinsson B, Wadell G. Rapid typing of human adenosviruses by a general PCR combined with restriction endonuclease analysis. J Clin Microbiol. 2001;39:498–505.
19. Maisch B, Portig J, Ristic AD, Hufnagel G, Pankuweit S. Definition of inflammatory cardiomyopathy: myocardiitis on the way to consensus – a status report. Herz. 2000;25:200–9.
20. D’Ambrosio A, Patti G, Manzoli A, Sinagra G, Di Lenarda A, Silvestri F, et al. The fate of acute myocardiitis between spontaneous improvement and evolution to dilated cardiomyopathy: a review. Heart. 2001;85:499–504.
21. Grogan M, Redfield MM, Bailey KR, Reeder GS, Gersh BJ, Edwards WD, et al. Long-term outcome of patients with biopsy-proven myocarditis comparison with idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 1995;26:580–4.
22. Rao M, Jaber BL, Balakrishnan VS. Inflammatory biomarkers and cardiovascular risk association or cause and effect? Semin Dial. 2006;19:129–35.
23. Carty CL, Heagerty P, Heckbert SR, Enquobahrie DA, Janik GP, Davis S, et al. Association of genetic variation in serum amyloid-A with cardiovascular disease and interactions with IL6, IL1RN, IL2BRA and TNF genes in the Cardiovascular Health Study. J Atheroscler Thromb. 2009;16:19–30.
24. Yamagishi S, Inagaki Y, Nakamura K, Abe R, Shimizu T, Yoshimura A, et al. Phenotype epithelium-derived factor inhibits TNF-alpha-induced interleukin-6 expression in endothelial cells by suppressing NADPH oxidase-mediated reactive oxygen species generation. J Mol Cell Cardiol. 2004;37:497–506.
25. Kobara M, Noda K, Kitamura M, Okamoto A, Shirai T, Toba H, et al. Antibody against interleukin-6-receptor attenuates left ventricular remodelling after myocardial infarction in mice. Cardiovasc Res. 2010;87:424–30.
26. Janssen SP, Gayan-Ramirez G, Van den Bergh A, Herijgers P, Maes K, Verbeken E, et al. Interleukin-6 causes myocardial failure and skeletal muscle atrophy in rats. Circulation. 2005;111:1996–1995.
27. Finkel MS, Odds CV, Jacob TD, Watkins SC, Hattler BG, Simmons RL. Negative inhibitory effects of cytokines on the heart mediated by nitric oxide. Science. 1992;257:383–7.
28. Villegas S, Villareal FJ, Dillmann WH. Leukemia inhibitory factor and interleukin-6 down regulates sarcoplasmic reticulum Ca2+ ATPase (SERCA2) in cardiac myocytes. Basic Res Cardiol. 2000;95:547–54.
29. Mir SA, Chatterjee A, Mitra A, Pathak K, Mahata SK, Sarkar S. Inhibition of signal transducer and activator of transcription 3 (STAT3) attenuates interleukin-6 (IL-6)-induced collagen synthesis and resultant hypertrophy in rat heart. J Biol Chem. 2012;287:2666–77.
30. Ji C, Chen X, Gao C, Jiao L, Wang J, Xu G, et al. IL-6 induces lipolysis and mitochondrial dysfunction, but does not affect insulin-mediated glucose transport in 3 T3-L1 adipocytes. J Bioenerg Biomembr. 2011:43:367–75.
31. White J, Dawson B, Landers G, Croft K, Peeling P. Effect of supplemental oxygen on post-exercise inflammatory response and oxidative stress. Eur J Appl Physiol. 2013;113:1059–67.
32. Kaneko K, Kanda T, Yamauchi Y, Hayasega A, Iwasaki T, Arai M, et al. C-Reactive protein in dilated cardiomyopathy. Cardiology. 1999;91:215–9.
33. Yang J, Wang J, Zhu S, Chen X, Wu H, Yang D, et al. C-C reactive protein augments hypoxia-induced apoptosis through mitochondria-dependent pathway in cardiac myocytes. Mol Cell Biochem. 2008;310:215–26.
34. Chu H, Lin Y, Chen JW, Jen HL, Chang MC, Huang WP, Feng AN, et al. Independent prognostic value of elevated high-sensitivity C-reactive protein in chronic heart failure. Am Heart J. 2004;147:931–8. 26.
35. Nakagomi A, Seino Y, Endoh Y, Kusama Y, Atarashi H, Mizuno K. Upregulation of monocyte proinflammatory cytokine production by C-reactive protein is significantly correlated to ongoing myocardial damage and future cardiac events in patients with chronic heart failure. J Card Fail. 2010;16:562–71.
36. Jug B, Salobir BG, Vene N, Sebestjen M, Sabovic M, Keber I. Interleukin-6 is a stronger prognostic predictor than highsensitive C-reactive protein in patients with chronic stable heart failure. Heart Vessels. 2009;24:271–6.

37. Konstantinidis K, Whelan RS, Kitsis RN. Mechanisms of cell death in heart disease. Arterioscler Thromb Vasc Biol. 2012;32:1552–62.

38. Chou JJ, Li H, Salvesen GS, Yuan J, Wagner G. Solution structure of Bid, an intracellular amplifier of apoptotic signaling. Cell. 1999;96:615–24.

39. Roucou X, Montessuit S, Antonsson B, Martinou JC. Bax oligomerization in mitochondrial membranes requires tBid (caspase-8-cleaved Bid) and a mitochondrial protein. Biochem J. 2002;368:915–21.

40. Wollert KC, Heineke J, Westermann J, Ludde M, Fiedler B, Zierhut W, et al. The cardiac Fas (APO-1/CD95) Receptor/Fas ligand system: relation to diastolic wall stress in volume-overload hypertrophy in vivo and activation of the transcription factor AP-1 in cardiac myocytes. Circulation. 2000;101:1172–8.

41. Spinale FG, Coker ML, Thomas CV, Walker JD, Mukherjee R, Hebbar L. Time-dependent changes in matrix metalloproteinase activity and expression during the progression of congestive heart failure: relation to ventricular and myocyte function. Circ Res. 1998;82:482–95.

42. Fares RC, Gomes Jde A, Garzoni LR, Waghabi MC, Saraiva RM, Medeiros NI, et al. Matrix metalloproteinases 2 and 9 are differentially expressed in patients with indeterminate and cardiac clinical forms of Chagas disease. Infect Immun. 2013;81:3600–8.

43. Ovechkin AV, Tyagi N, Rodriguez WE, Hayden MR, Moshal KS, Tyagi SC. Role of matrix metalloproteinase-9 in endothelial apoptosis in chronic heart failure in mice. J Appl Physiol (1985). 2005;99:2398–405.